Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
Thermo Fisher Scientific (TMO) reported insider activity by Chairman & CEO Marc N. Casper. On 10/24/2025 and 10/27/2025, he exercised stock options for 17,104 and 7,250 shares, respectively, at an exercise price of $253.99 per share, and sold the same number of shares on each date in multiple transactions at weighted average prices as disclosed.
Following these transactions, his direct beneficial ownership was 113,762.285 shares. He also reported indirect holdings of 11,300 shares by the Alison Casper 2020 Irrevocable Trust, 14,608 shares by Floral Park Associates, Inc., and 5,000 shares by the MNC 2020 Irrevocable Trust. The trades were conducted under a Rule 10b5-1 trading plan adopted on April 28, 2025.
Thermo Fisher Scientific (TMO): Form 144 notice of proposed sale. A holder filed to sell 7,250 shares of common stock, showing an aggregate market value of $4,104,237.84. The approximate sale date is 10/27/2025, with the shares listed on the NYSE. The filing lists 377,612,121 shares outstanding. The broker named is Fidelity Brokerage Services LLC.
The shares to be sold were acquired on 10/27/2025 via an option originally granted on 02/26/2019, with payment stated as cash. The notice also reports recent sales by Marc N. Casper, including 10,000 shares on 08/06/2025 for $4,518,207.00 and 17,104 shares on 10/24/2025 for $9,809,820.07.
TMO: A stockholder filed a Form 144 notice to sell up to 17,104 common shares with an aggregate market value of $980,820.29. The notice lists Fidelity Brokerage Services LLC as broker, an approximate sale date of 10/24/2025, and trading on the NYSE.
The filing shows these shares were acquired on 10/24/2025 via an option granted on 02/26/2019, with payment noted as cash. As context, 377,612,121 shares were outstanding.
Recent activity reported by the same seller over the past three months includes 10,000 shares on 08/06/2025 for $4,518,207.00 and 8,000 shares on 08/07/2025 for $3,635,549.60, among other smaller transactions.
Thermo Fisher Scientific (TMO) filed a Form 144 notice for a proposed sale of 400 common shares on or about 10/24/2025 through Fidelity Brokerage Services LLC on the NYSE. The filing lists an aggregate market value of $229,660. Shares outstanding were 377,612,121.
The shares to be sold were acquired via restricted stock vesting on 02/28/2024 (87 shares), 05/05/2024 (125 shares), and 08/23/2024 (188 shares). In the past three months, Gianluca Pettiti sold 400 shares on 07/25/2025 for $191,992 in gross proceeds.
The signer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
Thermo Fisher Scientific (TMO) furnished an update on its financial results by filing an Item 2.02 Form 8‑K. The company announced results for the fiscal quarter ended September 27, 2025 and provided the full details in a press release furnished as Exhibit 99.1.
The information is furnished and not deemed filed under Section 18 of the Exchange Act. Additional materials include the Cover Page Interactive Data File (Exhibit 104).
Thermo Fisher Scientific sold a new series of notes under an underwriting agreement entered on September 30, 2025 and reported the related event on October 7, 2025. The company expects net proceeds of approximately $2.48 billion after underwriting discounts and offering expenses.
The company intends to use the net proceeds for general corporate purposes, which may include acquisitions, repayment and refinancing of debt, working capital, capital expenditures, repurchases of equity securities, or temporary investment in short-term liquid instruments. The Underwriting Agreement is filed as Exhibit 1.1; a Twenty-Ninth Supplemental Indenture is filed as Exhibit 4.2, and a legal opinion and consent from its counsel are filed as Exhibit 5.1/23.1.
Dion J. Weisler, a director of Thermo Fisher Scientific, reported a Section 16 transaction dated 09/27/2025. The filing shows Phantom Stock Units were acquired under the company's Deferred Compensation Plan for Directors and are convertible 1-for-1 into common stock. The report states units were credited at $464.24 per unit and lists 80.78 as the number associated with the reported acquisition and 2,573.95 as the amount of common stock beneficially owned following the transaction. The units are distributable as stock upon cessation of director service or a change of control. The form was signed by an attorney-in-fact on 09/30/2025.
Scott M. Sperling, a director associated with Thomas H. Lee Partners, received 17,428.67 phantom stock units in Thermo Fisher Scientific (TMO) on 09/27/2025 under the company's Deferred Compensation Plan for Directors. Each unit is convertible into one share of common stock on a 1-for-1 basis and was credited at a per-unit value of $464.24, reflecting the quarter-end closing price used to calculate director retainer deferrals. The units are distributable as shares when director service ends or if a change of control occurs. The filing documents a grant of stock-linked deferred compensation rather than an open-market purchase or sale.
Keith R. Alexandra, a director of Thermo Fisher Scientific (TMO), reported a grant of 67.31 Phantom Stock Units credited on 09/27/2025 under the company's Deferred Compensation Plan for Directors. The units convert into common stock on a 1-for-1 basis and were credited at a recorded price of $464.24 per unit. The filing shows 1,150.49 shares beneficially owned following the reported transaction. The Plan states deferred director retainers are recorded as common stock units based on quarter-end closing prices and are distributable as stock upon cessation of director service or a change of control. The Form 4 was signed by an attorney-in-fact on 09/30/2025.
Karen S. Lynch, a director of Thermo Fisher Scientific (TMO), was credited with 67.31 phantom stock units on 09/27/2025 under the company's Deferred Compensation Plan for Directors. Each unit is convertible 1-for-1 into common stock and was recorded at a deferred unit price of $464.24 per unit. The units are payable as shares upon the director's cessation of service or upon a change of control. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Lynch on 09/30/2025. Following the reported transaction, the filing indicates 171.54 derivative units beneficially owned in a direct form.